Scott L. Friedman, MD
Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at Icahn School of Medicine at Mount Sinai« Back
Scott Friedman, MD, is Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at Icahn School of Medicine at Mount Sinai. He has performed pioneering research into the underlying causes of fibrosis associated with chronic liver disease. He was among the first to isolate and characterize the hepatic stellate cell, the key cell type responsible for scar production in liver. His work has spawned an entire field now reaching its translational and therapeutic potential with new anti-fibrotic therapies for liver disease moving into clinical trials.
Dr. Friedman received his medical degree from the Icahn School of Medicine and was a medical resident at the Beth Israel Hospital, Harvard Medical School, followed by a Gastroenterology Fellowship at UCSF and a faculty position there, which he held for ten years. Dr. Friedman has given invited honorary lectures throughout the world and is widely recognized as a dynamic speaker. He is also the author or more than 300 peer-reviewed publications.Next »